No abstract is provided for this article.
Selective metal powder sintering is a layer‐by‐layer manufacturing system producing metallic parts with good mechanical properties. Describes why an Fe‐Cu powder mixture has been selected as the basic material for the process. Deals with the powder deposition issue and proposes a mechanism which can deposit thin powder layers on top of a recipient. Shows that the powder deposition mainly depends on the powder properties. States that the required powder properties are partially compatible with the specifications set by the technology of selective sintering but that some properties are in conflict with one another. Discusses the resulting compromises needed in the powder mixtures and the required modifications to the deposition mechanism.
Human immunodeficiency virus (HIV) is the primary infectious agent of acquired immunodeficiency syndrome (AIDS), and non-nucleoside reverse transcriptase inhibitors (NNRTIs) are the cornerstone of HIV treatment. In the last 20 years, our medicinal chemistry group has made great strides in developing several distinct novel NNRTIs, including 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT), thio-dihydro-alkoxy-benzyl-oxopyrimidine (<i>S</i>-DABO), diaryltriazine (DATA), diarylpyrimidine (DAPY) analogues, and their hybrid derivatives. Application of integrated modern medicinal strategies, including structure-based drug design, fragment-based optimization, scaffold/fragment hopping, molecular/fragment hybridization, and bioisosterism, led to the development of several highly potent analogues for further evaluations. In this paper, we review the development of NNRTIs in the last two decades using the above optimization strategies, including their structure-activity relationships, molecular modeling, and their binding modes with HIV-1 reverse transcriptase (RT). Future directions and perspectives on the design and associated challenges are also discussed.